A combined screening platform for HIV treatment failure and resistance

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Tilghman, Myres W ^a   May, Susanne ^c   Pérez Santiago, Josué ^d   Ignacio, Caroline C ^a   Little, Susan J ^a   Richman, Douglas D ^a,b,d   Smith, Davey M ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; POL PROTEIN; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; DILUTION; ECONOMIC ASPECT; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RNA SEQUENCE; SCREENING TEST; SENSITIVITY ANALYSIS; TREATMENT FAILURE; VIRUS DETECTION; VIRUS LOAD; BLOOD; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD; YOUNG ADULT;

EID: 84860359387     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035401     Document Type: Article

References (11)

1. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304: 321-333.
2. May S, Gamst A, Haubrich R, Benson C, Smith DM, (2010) Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection. J Acquir Immune Defic Syndr 53: 194-201.
3. Smith DM, May SJ, Perez-Santiago J, Strain MC, Ignacio CC, et al. (2009) The use of pooled viral load testing to identify antiretroviral treatment failure. AIDS 23: 2151-2158.
4. Tilghman MW, Guerena DD, Licea A, Perez-Santiago J, Richman DD, et al. (2011) Pooled nucleic acid testing to detect antiretroviral treatment failure in Mexico. J Acquir Immune Defic Syndr 56: e70-74.
5. van Zyl GU, Preiser W, Potschka S, Lundershausen AT, Haubrich R, et al. (2011) Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a resource-limited setting. Clin Infect Dis 52: 264-270.
6. Martinez V, Marcelin AG, Morini JP, Deleuze J, Krivine A, et al. (2005) HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 19: 1065-1069.
7. Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, et al. (2005) Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 293: 817-829.
8. Gunthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, et al. (1998) Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 72: 2422-2428.
9. Gunthard HF, Wong JK, Ignacio CC, Havlir DV, Richman DD, (1998) Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses 14: 869-876.
10. Shafer RW, (2006) Rationale and uses of a public HIV drug-resistance database. J Infect Dis 194 (Suppl 1): S51-58.
11. Dorfman R, (1943) The detection of defective members of large populations. Annals of Mathematical Statistics 14: 436-440.